{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:32Z","timestamp":1786982132424,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01416-8","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T14:48:47Z","timestamp":1743086927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Central Nervous System Manifestations of Cutaneous Lymphomas"],"prefix":"10.1007","volume":"25","author":[{"given":"Ambar","family":"Chakravarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"1416_CR1","unstructured":"Sutton AM, Yadira H. Clinical practice guidelines for cutaneous lymphomas. Science of medicine| dermatology 2015 Jul-Aug;112(4):292\u20135."},{"key":"1416_CR2","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u201385.","journal-title":"Blood"},{"issue":"2","key":"1416_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2014.10.019","volume":"72","author":"M Desai","year":"2015","unstructured":"Desai M, Shuling L, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern united States: A single-institution cohort. J Am Acad Dermatol. 2015;72(2):276\u201385.","journal-title":"J Am Acad Dermatol"},{"key":"1416_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1067\/mjd.2002.118538","volume":"46","author":"EC Vonderheid","year":"2002","unstructured":"Vonderheid EC, Bernengo MG, Burg G, et al. Up-date on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas. J Am Acad Dermatol. 2002;46:95\u2013106.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1416_CR5","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FAMJ, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30\u2009+\u2009lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653\u201361.","journal-title":"Blood"},{"issue":"2","key":"1416_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","volume":"111","author":"R Willemze","year":"2008","unstructured":"Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC cutaneous lymphoma group study of 83 cases. Blood. 2008;111(2):838\u201345.","journal-title":"Blood"},{"key":"1416_CR7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","volume":"112","author":"NJ Senff","year":"2008","unstructured":"Senff NJ, Noordijk EM, Kim YH, et al. European organization for research and treatment of cancer and international society for cutaneous lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600\u20139.","journal-title":"Blood"},{"key":"1416_CR8","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","volume":"19","author":"F Grange","year":"2001","unstructured":"Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19:3602\u201310.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1416_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857\u201366.","journal-title":"Arch Dermatol"},{"issue":"31","key":"1416_CR10","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis Fungoides\/S\u00e9zary syndrome: validation of the revised international society for cutaneous lymphomas\/european organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1416_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hon.2850","volume":"39","author":"W Kempf","year":"2021","unstructured":"Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas\u2013 an update 2021. Hematol Oncol. 2021;39(Suppl 1):46\u201351.","journal-title":"Hematol Oncol"},{"issue":"3","key":"1416_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","volume":"37","author":"M Pulitzer","year":"2017","unstructured":"Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med. 2017;37(3):527\u201346.","journal-title":"Clin Lab Med"},{"issue":"1","key":"1416_CR13","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.clml.2013.09.016","volume":"14","author":"G Zhao","year":"2014","unstructured":"Zhao G, Chamberlain MC, Khot SP, Shustov A, Olerud JE, Shinohara MM. Central nervous system involvement in cutaneous T-cell lymphoma: 2 illustrative cases and a review of current literature. Clin Lymph Myel Leuk. 2014;14(1):e25\u201330.","journal-title":"Clin Lymph Myel Leuk"},{"key":"1416_CR14","first-page":"14","volume":"8","author":"Y Yang","year":"2017","unstructured":"Yang Y, Wickless H. Thinking about CNS metastasis in cutaneous lymphoma: analysis of existing data. Leuk Res Rep. 2017;8:14\u20138.","journal-title":"Leuk Res Rep"},{"issue":"10","key":"1416_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ajh.26299","volume":"96","author":"AC Hristov","year":"2021","unstructured":"Hristov AC, Tejasvi T, Wilcox RA, Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(10):1313\u201328.","journal-title":"Am J Hematol"},{"issue":"9","key":"1416_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clml.2023.05.001","volume":"23","author":"TZ Zhuang","year":"2023","unstructured":"Zhuang TZ, McCook-Veal A, Switchenko J, et al. Characterizing outcomes in visceral cutaneous T-cell lymphoma: a single center retrospective study. Clin Lymphoma Myel Leuk. 2023;23(9):667\u201373.","journal-title":"Clin Lymphoma Myel Leuk"},{"issue":"3","key":"1416_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000494081","volume":"11","author":"GL Jensen","year":"2018","unstructured":"Jensen GL, Dabaja BS, Pinnix CC, et al. Radiotherapy in patients with mycosis fungoides and central nervous system involvement. Case Rep Oncol. 2018;11(3):721\u20138.","journal-title":"Case Rep Oncol"},{"key":"1416_CR18","doi-asserted-by":"crossref","unstructured":"Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J. Am. Acad. Dermatol.2008; 59(2), S16\u2013S22 (2008).","DOI":"10.1016\/j.jaad.2007.09.025"},{"issue":"5","key":"1416_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1034\/j.1600-0609.2000.9c119.x","volume":"64","author":"SL Chua","year":"2000","unstructured":"Chua SL, Seymour JF, Prince HM. Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides. Eur J Haematol. 2000;64(5):340\u20133.","journal-title":"Eur J Haematol"},{"issue":"12","key":"1416_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/cup.12395","volume":"41","author":"L Harrington","year":"2014","unstructured":"Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014;41(12):936\u201343.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"1416_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00130404-200601000-00010","volume":"12","author":"M Stein","year":"2006","unstructured":"Stein M, Farrar N, Jones GW, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55\u201362.","journal-title":"Cancer J"},{"key":"1416_CR22","unstructured":"Swerdlow SH, World Health Organization, International Agency for Research on Cancer WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017."},{"issue":"3","key":"1416_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.23638","volume":"89","author":"JJ Castillo","year":"2014","unstructured":"Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology and end results database. Am J Hematol. 2014;89(3):310\u20134.","journal-title":"Am J Hematol"},{"issue":"11","key":"1416_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041\u20136.","journal-title":"Am J Hematol"},{"issue":"9","key":"1416_CR25","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3109\/10428194.2010.504872","volume":"51","author":"D Hui","year":"2010","unstructured":"Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(9):1658\u201367.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"1416_CR26","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d\u2019etude des lymphomes de L\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1416_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol"},{"issue":"9880","key":"1416_CR28","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817\u201326.","journal-title":"Lancet"},{"issue":"2","key":"1416_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381.","journal-title":"Blood"},{"key":"1416_CR30","doi-asserted-by":"crossref","unstructured":"Ferreri AJ. Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol. 2014;15(4):e159\u201369.","DOI":"10.1016\/S1470-2045(13)70568-0"},{"issue":"17","key":"1416_CR31","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin lymphoma study group (DSHNHL). Blood. 2009;113(17):3896\u2013902.","journal-title":"Blood"},{"issue":"10","key":"1416_CR32","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","volume":"28","author":"M Gleeson","year":"2017","unstructured":"Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511\u20136.","journal-title":"Ann Oncol"},{"key":"1416_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","volume":"75","author":"TC El-Galaly","year":"2017","unstructured":"El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, et al. The number of extra nodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195\u2013203.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1416_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","volume":"91","author":"K van Besien","year":"1998","unstructured":"van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178\u201384.","journal-title":"Blood"},{"issue":"2","key":"1416_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1023\/A:1008260120532","volume":"9","author":"GM Bos","year":"1998","unstructured":"Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin\u2019s lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON group. Ann Oncol. 1998;9(2):191\u20134.","journal-title":"Ann Oncol"},{"issue":"7","key":"1416_CR36","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol. 2002;13(7):1099\u2013107.","journal-title":"Ann Oncol"},{"issue":"26","key":"1416_CR37","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150\u20136.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1416_CR38","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","volume":"130","author":"CK Chin","year":"2017","unstructured":"Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130(7):867\u201374.","journal-title":"Blood"},{"issue":"2","key":"1416_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjh.12509","volume":"163","author":"A McMillan","year":"2013","unstructured":"McMillan A, Ardeshna KM, Cwynarski K, Lyttelton M, McKay P, Montoto S, et al. Guideline on the prevention of secondary central nervous system lymphoma: British committee for standards in haematology. Br J Haematol. 2013;163(2):168\u201381.","journal-title":"Br J Haematol"},{"issue":"2","key":"1416_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3324\/haematol.2016.149120","volume":"102","author":"FJ Penalver","year":"2017","unstructured":"Penalver FJ, Sancho JM, de la Fuente A, Olave MT, Martin A, Panizo C, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish lymphoma group (GELTAMO). Haematologica. 2017;102(2):235\u201345.","journal-title":"Haematologica"},{"issue":"1","key":"1416_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.12841","volume":"166","author":"H Wu","year":"2014","unstructured":"Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, et al. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Br J Haematol. 2014;166(1):60\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"1416_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest oncology group. J Clin Oncol. 2009;27(1):114\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1416_CR43","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/cncr.26588","volume":"118","author":"A Kumar","year":"2012","unstructured":"Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large National database. Cancer. 2012;118(11):2944\u201351.","journal-title":"Cancer"},{"issue":"3","key":"1416_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/10428194.2013.811239","volume":"55","author":"J Zhang","year":"2014","unstructured":"Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(3):509\u201314.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1416_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ejh.12763","volume":"97","author":"MF Zahid","year":"2016","unstructured":"Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(2):108\u201320.","journal-title":"Eur J Haematol"},{"key":"1416_CR46","doi-asserted-by":"crossref","unstructured":"Klein A, Polliack A. Gafter-GviliA Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome Hematol Oncol 2018; Dec;36(5):733\u2013739.","DOI":"10.1002\/hon.2525"},{"key":"1416_CR47","doi-asserted-by":"crossref","unstructured":"Banko A, Miljanovic D, Lazarevic I, Jeremic I, Despotovic A, Grk M. CirkovicA. New evidence of significant association between EBV presence and lymphoproliferative disorders susceptibility in patients with rheumatoid arthritis: A systematic review with Meta-Analysis.Viruses. 2022;14(1):115.","DOI":"10.3390\/v14010115"},{"issue":"10","key":"1416_CR48","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/imj.15390","volume":"52","author":"J He","year":"2022","unstructured":"He J, Williamson L, Cai K, Wong P, Sturgess A, Taper J. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature. Manolios N Intern Med J. 2022;52(10):1717\u201323.","journal-title":"Manolios N Intern Med J"},{"issue":"5","key":"1416_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.19.00581","volume":"16","author":"E Lebel","year":"2020","unstructured":"Lebel E, Benshushan S, Paltiel O. From the skin straight to the brain: rare CNS recurrence of cutaneous anaplastic large cell lymphoma. ACJCO Oncol Pract. 2020;16(5):247\u20138.","journal-title":"ACJCO Oncol Pract"},{"issue":"9","key":"1416_CR50","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.5858\/arpa.2021-0165-RA","volume":"146","author":"JW Davis","year":"2022","unstructured":"Davis JW, Auerbach A, Crothers BA, Lewin E, Lynch DT, Teschan NJ, Schmieg JJ. Intravascular large B-Cell lymphoma. Arch Pathol Lab Med. 2022;146(9):1160\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"1416_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255\u201366.","journal-title":"Semin Hematol"},{"issue":"1","key":"1416_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12875-019-0954-3","volume":"20","author":"A Fugl","year":"2019","unstructured":"Fugl A, Andersen CL. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract. 2019;20(1):62.","journal-title":"BMC Fam Pract"},{"key":"1416_CR53","doi-asserted-by":"crossref","unstructured":"Balandraud N, Roudier J. Epstein-Barr virus and rheumatoid arthritis. J.Joint Bone Spine. 2018 Mar;85(2):165-170.","DOI":"10.1016\/j.jbspin.2017.04.011"},{"key":"1416_CR54","doi-asserted-by":"crossref","unstructured":"Kedra J, Seror R, Dieud\u00e9 P, Constantin A, Toussirot E, Kfoury E, Masson C, Cornec D, Dubost JJ, Marguerie L, Ottaviani S, Grados F, Belkhir R, Fain O, Goupille P, Sordet C, Fautrel B, Philippe P, Piperno M, Combe B, Lambotte O, Richez C, Sellam J, Sen\u00e9 T, Denis G, Lequerre T, Lazure T, Mariette X, Nocturne G. Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open. 2021;7(3):e001698.","DOI":"10.1136\/rmdopen-2021-001698"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01416-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01416-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01416-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:08:54Z","timestamp":1743318534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01416-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01416-8","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"11 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"27"}}